MEDIWOUND ($MDWD) is expected to release its quarterly earnings data on Wednesday, March 19th before market open, per Finnhub. Analysts are expecting revenue of $5,862,756 and earnings of -$0.62 per share.
You can see Quiver Quantitative's $MDWD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MEDIWOUND Hedge Fund Activity
We have seen 31 institutional investors add shares of MEDIWOUND stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- YELIN LAPIDOT HOLDINGS MANAGEMENT LTD. added 100,618 shares (+13.4%) to their portfolio in Q4 2024, for an estimated $1,791,000
- UNIPLAN INVESTMENT COUNSEL, INC. removed 71,164 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,285,221
- NORTHERN TRUST CORP added 70,367 shares (+94.6%) to their portfolio in Q4 2024, for an estimated $1,252,532
- UBS GROUP AG added 63,135 shares (+1714.7%) to their portfolio in Q4 2024, for an estimated $1,123,803
- ESSEX INVESTMENT MANAGEMENT CO LLC added 35,012 shares (+30.7%) to their portfolio in Q4 2024, for an estimated $623,213
- EAM INVESTORS, LLC removed 32,783 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $583,537
- RENAISSANCE TECHNOLOGIES LLC removed 23,026 shares (-66.9%) from their portfolio in Q4 2024, for an estimated $409,862
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MEDIWOUND Analyst Ratings
Wall Street analysts have issued reports on $MDWD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 10/11/2024
To track analyst ratings and price targets for MEDIWOUND, check out Quiver Quantitative's $MDWD forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
